How liquid biopsies are driving change in patient care

Liquid biopsies are emerging as a transformative diagnostic tool, offering a less invasive, faster, and more scalable alternative to traditional tissue biopsies. As molecular testing becomes central to precision medicine, will the diagnostic and payer ecosystem drive – or delay – broader adoption?

What are liquid biopsies?

Liquid biopsies are diagnostic tests that detect tumor-derived biomarkers such as circulating tumor DNA (ctDNA), RNA fragments, or exosomes through a simple blood draw. Compared to traditional tissue biopsies, they are minimally invasive, easier on patients, and less risky – especially for those with inaccessible or fragile tumors. They also provide a more comprehensive view of tumor heterogeneity by capturing molecular information from multiple tumor sites simultaneously.

The benefits extend across the patient journey and provider workflow. In early-stage diseases, research from …